Skip to main content
SpringerLink
Log in

Was leisten die neuen Onkologika?

Immuntherapie bei Lungenkrebs

  • aktuell
  • Published:
Pneumo News Aims and scope

Für die Behandlung von Patienten mit Lungenkarzinom gab es auch beim ASCO-Kongress 2019 wieder neue Entwicklungen, vor allem beim metastasierten nichtkleinzelligen Lungenkarzinom (NSCLC) und beim lokal begrenzten und lokal fortgeschrittenen NSCLC. Checkpointinhibitoren und auf onkogene Alterationen gerichtete Therapien treiben dabei die Entwicklung in der thorakalen Onkologie.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Socinski MA, Jotte RM, Cappuzzo F et al. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288–301

    Article  CAS  PubMed  Google Scholar 

  2. Ardizzoni A, Hansen H, Dombernowsky P et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol. 1997;15(5):2090–6

    Article  CAS  PubMed  Google Scholar 

  3. von Pawel J, Schiller JH, Shepherd FA et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 1999;17(2):658–67

    Article  Google Scholar 

  4. von Pawel J, Jotte R, Spigel DR et al. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol. 2014;32(35):4012–9

    Article  Google Scholar 

  5. Reck M, Vicente D, Ciuleanu T et al. Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): Results from CheckMate 331 Ann Oncol. 2018;29(suppl 10):x39–x43

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Innere Medizin IV Pneumologie / Intensivmedizin / Onkologie / Allergologie / Schlaf- und Beatmungsmedizin, Klinikum Chemnitz gGmbH, Flemmingstrasse 2, 09116, Chemnitz, Deutschland

    Stefan Hammerschmidt

  2. Tauchaer Straße 12, 04357, Leipzig, Deutschland

    Christian Geßner (Pneumologische Praxis)

Authors
  1. Stefan Hammerschmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christian Geßner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stefan Hammerschmidt.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hammerschmidt, S., Geßner, C. Immuntherapie bei Lungenkrebs. Pneumo News 11, 41–43 (2019). https://doi.org/10.1007/s15033-019-1249-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15033-019-1249-z

Search

Navigation